[go: up one dir, main page]

MX2011013201A - Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion. - Google Patents

Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.

Info

Publication number
MX2011013201A
MX2011013201A MX2011013201A MX2011013201A MX2011013201A MX 2011013201 A MX2011013201 A MX 2011013201A MX 2011013201 A MX2011013201 A MX 2011013201A MX 2011013201 A MX2011013201 A MX 2011013201A MX 2011013201 A MX2011013201 A MX 2011013201A
Authority
MX
Mexico
Prior art keywords
addiction
compositions
improving
related behavior
treating drug
Prior art date
Application number
MX2011013201A
Other languages
English (en)
Inventor
Sung James Lee
Susan Marie Melnick
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2011013201A publication Critical patent/MX2011013201A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una composición, a un uso de la composición y a un método para tratar la adicción a drogas que causan adicción en un sujeto, en donde la composición comprende un compuesto de cabamoilo, o sal o éster farmacéuticamente aceptable del mismo como un ingrediente activo, y el método comprende administrar una cantidad terapéuticamente efectiva de un compuesto de cabamoilo, o una sal o éster farmacéuticamente aceptable del mismo.
MX2011013201A 2009-06-26 2010-06-10 Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion. MX2011013201A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/492,566 US8232315B2 (en) 2009-06-26 2009-06-26 Methods for treating drug addiction and improving addiction-related behavior
PCT/KR2010/003742 WO2010150995A2 (en) 2009-06-26 2010-06-10 Compositions for treating drug addiction and improving addiction-related behavior

Publications (1)

Publication Number Publication Date
MX2011013201A true MX2011013201A (es) 2012-03-07

Family

ID=43381414

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013201A MX2011013201A (es) 2009-06-26 2010-06-10 Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.

Country Status (15)

Country Link
US (1) US8232315B2 (es)
EP (2) EP2445489B1 (es)
JP (1) JP5650208B2 (es)
KR (1) KR101461567B1 (es)
CN (2) CN102695502B (es)
AU (1) AU2010263469B2 (es)
BR (1) BRPI1015064A2 (es)
CA (1) CA2764665C (es)
DK (1) DK2445489T3 (es)
ES (2) ES2853730T3 (es)
MX (1) MX2011013201A (es)
PL (1) PL2445489T3 (es)
RU (1) RU2535046C2 (es)
TW (1) TWI483719B (es)
WO (1) WO2010150995A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI419681B (zh) 2005-06-08 2013-12-21 Ｓｋ生物製藥股份有限公司 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途
US20100086543A1 (en) * 2007-04-02 2010-04-08 Saint Louis University Compositions and methods for treating conditions associated with ceramide biosynthesis
JP6095366B2 (ja) 2009-06-22 2017-03-15 エスケー バイオファーマシューティカルズ カンパニー リミテッド 疲労を治療又は予防するための方法
CN102762201B (zh) 2009-11-06 2013-12-18 爱思开生物制药株式会社 注意力缺陷/多动症的治疗方法
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
PT2968208T (pt) 2013-03-13 2022-10-28 Aerial Biopharma Llc Tratamento da cataplexia
JP2016530240A (ja) * 2013-07-12 2016-09-29 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ 禁煙の促進
EP3021838B1 (en) 2013-07-18 2020-05-27 Jazz Pharmaceuticals Ireland Limited Treatment for obesity
TWI655179B (zh) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
ES2970887T3 (es) 2016-09-06 2024-05-31 Axsome Malta Ltd Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
WO2018067971A1 (en) 2016-10-06 2018-04-12 Jazz Pharmaceuticals International Iii Limited Carbamoyl phenylalaninol compounds and uses therof
EP3630072A4 (en) 2017-06-02 2021-03-10 Jazz Pharmaceuticals Ireland Limited METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
RU2020108634A (ru) 2017-07-31 2021-09-02 Джаз Фармасьютикалз Айрлэнд Лимитед Аналоги карбамоилфенилаланинола и способы их применения
CN110655500B (zh) * 2018-06-28 2020-12-08 浙江京新药业股份有限公司 氨基甲酸酯衍生物及其制备方法和用途
JP2019163298A (ja) * 2019-05-22 2019-09-26 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ 禁煙の促進
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
CN114667964B (zh) * 2020-12-24 2023-11-14 中国科学院脑科学与智能技术卓越创新中心 一种非人灵长类药物成瘾性评估的方法与应用
IL308069A (en) * 2021-05-05 2023-12-01 Mind Medicine Inc MDMA enantiomers
AU2024308064A1 (en) 2023-06-29 2026-01-22 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) * 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP0873308B1 (en) * 1996-10-10 2002-01-02 SK Corporation O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
AU4674797A (en) * 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
KR19980026988U (ko) * 1996-11-13 1998-08-05 김무 다용도 드레인밸브
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
TWI242004B (en) 1998-04-28 2005-10-21 Dainippon Pharmaceutical Co 1-(1-substituted-4-piperidinyl)methyl-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
US7259157B2 (en) 2001-04-03 2007-08-21 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
CA2449249A1 (en) 2001-06-12 2002-12-19 Merck & Co., Inc. Nr2b receptor antagonists for the treatment or prevention of migraines
CA2499494A1 (en) 2002-09-20 2004-04-01 Pfizer Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
EP1620435A1 (en) 2003-04-21 2006-02-01 Pfizer Inc. IMADAZOPYRIDINE COMPOUNDS HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY AND 5-HT sb 3 /sb RECEPTOR ANTAGONISTIC ACTIVITY
DK1664036T3 (da) 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
US20050080268A1 (en) * 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
NZ563238A (en) 2005-04-08 2011-01-28 Pfizer Prod Inc Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors
TWI419681B (zh) * 2005-06-08 2013-12-21 Ｓｋ生物製藥股份有限公司 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途
KR101199499B1 (ko) * 2005-07-26 2012-11-09 얀센 파마슈티카 엔.브이. 물질 관련 장애를 치료하는 방법
US8642772B2 (en) * 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use

Also Published As

Publication number Publication date
KR20120028342A (ko) 2012-03-22
EP2445489A2 (en) 2012-05-02
CN102695502A (zh) 2012-09-26
PL2445489T3 (pl) 2020-05-18
JP5650208B2 (ja) 2015-01-07
CN102695502B (zh) 2014-12-24
HK1176285A1 (en) 2013-07-26
US20100331332A1 (en) 2010-12-30
JP2012531405A (ja) 2012-12-10
CA2764665C (en) 2018-07-03
CN104490859B (zh) 2017-09-22
CA2764665A1 (en) 2010-12-29
ES2766272T3 (es) 2020-06-12
DK2445489T3 (da) 2020-01-27
EP3552604A1 (en) 2019-10-16
WO2010150995A3 (en) 2011-04-28
HK1209058A1 (en) 2016-03-24
WO2010150995A2 (en) 2010-12-29
TWI483719B (zh) 2015-05-11
AU2010263469B2 (en) 2015-02-05
ES2853730T3 (es) 2021-09-17
CN104490859A (zh) 2015-04-08
EP2445489B1 (en) 2019-10-30
RU2535046C2 (ru) 2014-12-10
TW201103531A (en) 2011-02-01
AU2010263469A1 (en) 2012-01-19
EP2445489A4 (en) 2013-05-29
BRPI1015064A2 (pt) 2016-04-19
KR101461567B1 (ko) 2014-11-26
EP3552604B1 (en) 2020-12-16
RU2011150654A (ru) 2013-08-10
US8232315B2 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
EP2562177A3 (en) Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
NZ602510A (en) Treatment of lupus nephritis using laquinimod
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
PH12012501741A1 (en) Treatment of lupus arthritis using laquinimod
TW200806299A (en) Treatment of pain
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2012007159A3 (en) Novel gastro-retentive dosage forms
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2013085849A3 (en) Sulfate esters of noribogaine
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
TNSN08506A1 (en) Substituted carboxamides
TW201129361A (en) Methods for treating pain
MX2014001823A (es) Combinaciones de corroles y estatinas.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
WO2014015137A3 (en) Compositions and methods for treating dysproliferative diseases

Legal Events

Date Code Title Description
FG Grant or registration